Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 22, 2016 22:08:09 GMT -5
Since William McCullough is on the west coast, it could also be because of that. Not sure where New York came from, unless I am missing the part where any of this has to do with New York. No. VDEX is a corporation and as such it's own person and it lives in Delaware being that is where it is incorporated. Since it wishes to trade in California it must register as a foreign corporation there. If you do substantial business in a state other than the home state without being registered as a foreign corporation you are open to substantial fines. The New York reference was an example. A New York corporation ends up often having to register as a foreign corporation in New Jersey and possibly Connecticut because almost inevitably you do substantial business in those states if you are in the tri-state area. You are right. A little over a month ago, William "Bill" McCullough, owner of Samson Hair Restoration, Famsee, Inc., Vdex trademarks, and now, Vdex Diabetes Holdings, Inc.
|
|
|
Post by dreamboatcruise on Jul 26, 2016 22:13:19 GMT -5
I wonder if they realize that Videx is a drug that some apparently believe causes diabetes. A week or so ago I just randomly thought to check on the VDex site but had apparently forgotten the name, so I typed Videx Diabetes into google search. Hopefully that doesn't cause confusion in their branding.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 26, 2016 22:49:37 GMT -5
No ... Typed in with out much thought but you get my point... Was it standard language or something specific to you and vdex? I'm not trying to be a SA, but I do not get your point. Since when do clinics issue a confidentiality notice in an email? There is a difference between a confidentiality notice and a disclaimer statement.
|
|
|
Post by agedhippie on Jul 27, 2016 7:40:38 GMT -5
I wonder if they realize that Videx is a drug that some apparently believe causes diabetes. A week or so ago I just randomly thought to check on the VDex site but had apparently forgotten the name, so I typed Videx Diabetes into google search. Hopefully that doesn't cause confusion in their branding. Hmm. Full lifecycle service
|
|
|
Post by mnkdfann on Jul 27, 2016 10:46:48 GMT -5
Another Vdex. Maybe 'ours' can latch onto the renewed popularity of Pokémon. "The VirtualDex Project, or VDex for short, is a text-based browser game based on the popular Pokémon franchise." vdexproject.net/
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 27, 2016 23:29:42 GMT -5
I wonder if they realize that Videx is a drug that some apparently believe causes diabetes. A week or so ago I just randomly thought to check on the VDex site but had apparently forgotten the name, so I typed Videx Diabetes into google search. Hopefully that doesn't cause confusion in their branding. Lol. Most ridiculous thing I have ever heard!
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 31, 2016 16:31:12 GMT -5
I wonder if they realize that Videx is a drug that some apparently believe causes diabetes. A week or so ago I just randomly thought to check on the VDex site but had apparently forgotten the name, so I typed Videx Diabetes into google search. Hopefully that doesn't cause confusion in their branding. Hmm. Full lifecycle service The FUD Factor in full working order!
|
|
|
Post by veritasfiliatemporis on Sept 18, 2016 7:25:08 GMT -5
So we can say the original plan to open in New Jersey has been delayed due to register problems??? Tks
|
|
|
Post by sportsrancho on Sept 18, 2016 9:17:34 GMT -5
This is from Pkgossett on ST.
Can Metformin Use Increase The Risk Of Diabetic Neuropathy?
Monday, 03/01/10 | 16485 reads Allen Jacobs DPM FACFAS 140 0 8 googleplus3 Metformin (Glucophage, Bristol-Myers Squibb) is a commonly utilized biguanide agent for the treatment of diabetes. Increasingly, it appears that metformin may paradoxically increase the risk of neuropathy in the patient with diabetes. Therefore, when you see a patient with diabetes who is taking metformin, greater surveillance may be necessary for the presence of sensory, autonomic and motor neuropathy.
Wile and colleagues noted that metformin increases homocysteine levels as well as methylmalonic acid levels, both contributing factors to neuropathy.1 The study noted the increased frequency and severity of diabetic neuropathy in patients taking metformin, as well as reduced levels of B12.
In a recent issue of Diabetes Care, Palomba and co-workers also affirmed that metformin raises serum homocysteine levels with resultant endothelial dysfuction.2 They suggested that folate supplementation may be helpful in reducing this effect.
The suggestion that metformin may act to raise homocysteine levels is not new as others have suggested that more than six months of exposure to metformin results in rising homocysteine levels.3,4
Studies have previously suggested that elevated levels of homocysteine to be operative may play a role in the evolution of diabetic neuropathy.5
Metformin interferes with the absorption of vitamin Band, as a result, the chronic use of metformin may act to reduce vitamin B levels in the patient with diabetes. Vitamin B compounds are critical for normal nerve health and function. Accordingly, a reduction in the level of vitamin B may result in an increased incidence of neuropathy in those taking metformin.6
In addition, L-methyl folate (Metanx, Pamlab), the active form of folic acid, directly stimulates nitric oxide production, increasing blood flow to neural tissue and reversing endothelial dysfunction. L-methyl folate, pyridoxine and cobalamin are essential for the reduction of homocysteine. Homocysteine, a non-essential amino acid, increases the incidence of neuropathy by reducing blood flow to neural tissue (and wounds) by inducing vascular thrombosis and reducing levels of nitric oxide available for vasodilation.
Additionally, the kidneys clear homocysteine from the system and in the patient with decreasing renal mass, increased levels of homocysteine may also occur.
Epidermal nerve fiber density testing in the patient taking metformin frequently demonstrates significant evolving loss of nerve fiber density, even in the patient without neuropathy associated complaints or concerns. Supplementation with L-methyl folate, vitamin B6 and B12 may reverse the progression of this pathology in some patients. Remember that many individuals cannot convert OTC folic acid to the necessary active form. Therefore, these patients may derive little or no benefit from OTC vitamin B preparations.
Final Notes
One should carefully evaluate any patient taking metformin for longer than six months for occult and unappreciated sensory, motor or autonomic neuropathy. Recognition and quantification with epidermal nerve fiber density testing allows assessment of the extent of disease as well as the response to management. Neuropathy is a major risk factor for ulceration and amputation. Early interdiction of the progress of neuropathy may result in a lower risk of amputation.
Editor’s note: Dr. Jacobs is a lecturer for Pamlab.
References
1. Wile DJ, Toth C. Scientific sessions, American Academy of Neurology. April 29, 2009.
2. Palombas. S, Falbo A, Giallauria F, et al. Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome. Diabetes Care 2010; 33(2):246-51. 2010
3. Omrani GHR, Lari OB, Mehdizadeh AR, et al. Comparison of serum homocysteine level in metformin versus glibenclamide treated type 2 dm patients. Iranian J . Diab and Lipid Dis 2004; 4 (2):95. 2005
4. Hermann LS, Nilsson B, Wettre S. Vitamin B12 status of patients treated with metformin: a cross-sectional cohort study. Br J Diabetes Vasc Dis 2004; 4(6):401–6.
5. Ambrosch A, Dierkes J, Lobmann R, et al. Relation between homocysteinaemia and diabetic neuropathy in patients with Type 2 diabetes mellitus. Diabet Med 2001 Mar;18(3):185-92.
6. Braza M, Hanley J, Bhatia A, Martinez M. Prevalence of vitamin B12 deficiency in Hispanic patients with type 2 diabetes mellitus (DM) on long-term metformin — is it associated with peripheral neuropathy? Presented at American Diabetes Association 69th Annual Scientific Sessions, New Orleans, June 5-9, 2009.
|
|
|
Post by sportsrancho on Sept 18, 2016 9:22:37 GMT -5
sportsrancho Postaholic 6 hours ago liane, sla4235, and 2 more like this Quote pkgossett • 7 hours ago 3users liked this postsusers disliked this posts0Reply Ok POS, let's, they are low because PCP's, who are primary Afrezza prescribers, are unwilling and unable to educate patients on proper dosing. Almost EVERY T2 I have spoken with are on METFORMIN, a huge difference from popping a pill that any moron PCP can prescribe, when it comes to Afrezza the patient must be EDUCATED on how to calculate and titrate dosage, PCP's are incapable of doing this because don't get PAID to do so. It is ALL about education and disease mgmt. Endo's don't want the hassle, METFORMIN is easy and T2's are numerous. Endo's are overwhelmed, don't believe me, call and try to get an appointment. VDEX is 100% correct that diabetes education and mgmt is a massive niche that nobody has filled. Why are they interested in us? We have 17 clinics with another 30 ready to open, over half our patients are diabetics, I have NEVER had a diabetic not be interested in Afrezza when told them about but when they ask PCP they have never heard of it and wouldn't know how to prescribe it if did. Toss in the Spiro issue and pre-auth and u have one heck of an obstacle. Now do you see the niche? I sure as heck do. Now say VDEX is ready to a) Spiro patients B) hold hand through insurance obstacles c) educate patients on dosage, usage and titration d) help patient "manage" disease. You get the picture now? Now throw in our 17 clinics and 300 NEW diabetics we see weekly who are, without objection, ready to be guided to manage diabetes. We have perfect harmony. Can't and won't go into much more detail but NJ clinic almost happened but ran into issues, California WILL happen very soon and it could be the beginning of a beautiful relationship. Now let's address your $$$$ objection, our 17 centers do not take insurance yet all are hugely successful, why you may ask? Because patients are willing to pay for results and with insurance reform and deductibles sky-rocketing a "cash" environment is ripe. Get it now? Probably not cuz can't educate folks like you. pkgossett • 3 hours ago Flag 0users liked this postsusers disliked this posts0Reply It won't be full freight for the majority, doctors scoffed at our nerve center concept and all are doing 7 figures. Like our nerve centers, once you get momentum everyone wants in. Mannkind has a tough road ahead but if we can get Medicaid patients paying $4-5,000 for Neuropathy treatment we can get them to pay for diabetes mgmt. Once patients spread word of success it will snowball and snowball rapidly. Most of the money has been spent developing and bringing Afrezza to market, the packaging costs more than the drug, that's why drug companies are so profitable. We aren't speaking with VDEX to profit, we need to control our patients diabetes so our treatment will be more effective. We can treat their neuropathy but diabetes and BS spikes are cause. We need help with the cause, VDEX and Afrezza are an answer, will know more by end of month on how they plan to monetize it but we are willing to funnel our diabetics to them for care Less Sentiment: Strong Buy Read more: Good posts from YMB
|
|
|
Post by snowballsmommy on Sept 18, 2016 19:08:08 GMT -5
On this note....my husband's endo would not prescribe Afrezza for him. (we are in NJ). Took the list that showed MD's by state that are prescribing Afrezza. Waited 4 months for an appointment for a doctor listed that is part of a "diabetes and endocrine specialty practice." During his appointment, never stated that we were investors. Just asked about Afrezza. He gave a sneer, and said, I am not prescribing Afrezza. We went over the fact that several of our friends are on it and how great they feel, and all the attributes. He wanted to hear nothing. He wants to prescribe a once weekly shot instead. Left the appointment very depressed. It is so obvious that patients have to be the drive. These guys are so in bed with big pharma that it does not matter UNLESS enough patients demand it.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Sept 18, 2016 19:14:46 GMT -5
On this note....my husband's endo would not prescribe Afrezza for him. (we are in NJ). Took the list that showed MD's by state that are prescribing Afrezza. Waited 4 months for an appointment for a doctor listed that is part of a "diabetes and endocrine specialty practice." During his appointment, never stated that we were investors. Just asked about Afrezza. He gave a sneer, and said, I am not prescribing Afrezza. We went over the fact that several of our friends are on it and how great they feel, and all the attributes. He wanted to hear nothing. He wants to prescribe a once weekly shot instead. Left the appointment very depressed. It is so obvious that patients have to be the drive. These guys are so in bed with big pharma that it does not matter UNLESS enough patients demand it. you are paying for his service. so you should have demanded an rx for Afrezza. I am guessing you are a T2 and the doc wants to push GLP1 and push your pancreas rather than meal time insulin. Its your health..so if you already know the benefits , demand one. if you want to be nice , ask samples may be and log your bg levels?
|
|
|
Post by nadathing on Sept 18, 2016 19:26:34 GMT -5
On this note....my husband's endo would not prescribe Afrezza for him. (we are in NJ). Took the list that showed MD's by state that are prescribing Afrezza. Waited 4 months for an appointment for a doctor listed that is part of a "diabetes and endocrine specialty practice." During his appointment, never stated that we were investors. Just asked about Afrezza. He gave a sneer, and said, I am not prescribing Afrezza. We went over the fact that several of our friends are on it and how great they feel, and all the attributes. He wanted to hear nothing. He wants to prescribe a once weekly shot instead. Left the appointment very depressed. It is so obvious that patients have to be the drive. These guys are so in bed with big pharma that it does not matter UNLESS enough patients demand it. I'm not surprised. Afrezza is insulin. I am on Trulicity and my A1c is 5.7. Until I am insulin dependent or unable to control my blood sugars, I will not be using Afrezza. I would imagine that most endos prescribe insulin only after other treatments fail to adequately control diabetes. Afrezza may or may not be a better choice for your husband than Trulicty or another GLP-1, but his endo is not inclined to prescribe it for him. It would be interesting to hear from other T2's who have tight control over their diabetes using more traditional treatment and yet were precribed Afrezza as an alternative. I am also aware of the potential risks of using a GLP-1, but I can also say that convenience of a once weekly injection, which is relatively painless, outweighs using an inhaler 3 times a day. I am a staunch supporter of MNKD and I've been invested 7+ years, but I also know that not everyone is a candidate for Afrezza.
|
|
|
Post by peppy on Sept 18, 2016 19:26:37 GMT -5
On this note....my husband's endo would not prescribe Afrezza for him. (we are in NJ). Took the list that showed MD's by state that are prescribing Afrezza. Waited 4 months for an appointment for a doctor listed that is part of a "diabetes and endocrine specialty practice." During his appointment, never stated that we were investors. Just asked about Afrezza. He gave a sneer, and said, I am not prescribing Afrezza. We went over the fact that several of our friends are on it and how great they feel, and all the attributes. He wanted to hear nothing. He wants to prescribe a once weekly shot instead. Left the appointment very depressed. It is so obvious that patients have to be the drive. These guys are so in bed with big pharma that it does not matter UNLESS enough patients demand it. It sounds like you were in a sense demanding afrezza and he sad no. A mother and child reunion of sorts.
|
|
|
Post by peppy on Sept 18, 2016 19:34:12 GMT -5
On this note....my husband's endo would not prescribe Afrezza for him. (we are in NJ). Took the list that showed MD's by state that are prescribing Afrezza. Waited 4 months for an appointment for a doctor listed that is part of a "diabetes and endocrine specialty practice." During his appointment, never stated that we were investors. Just asked about Afrezza. He gave a sneer, and said, I am not prescribing Afrezza. We went over the fact that several of our friends are on it and how great they feel, and all the attributes. He wanted to hear nothing. He wants to prescribe a once weekly shot instead. Left the appointment very depressed. It is so obvious that patients have to be the drive. These guys are so in bed with big pharma that it does not matter UNLESS enough patients demand it. I'm not surprised. Afrezza is insulin. I am on Trulicity and my A1c is 5.7. Until I am insulin dependent or unable to control my blood sugars, I will not be using Afrezza. I would imagine that most endos prescribe insulin only after other treatments fail to adequately control diabetes. Afrezza may or may not be a better choice for your husband than Trulicty or another GLP-1, but his endo is not inclined to prescribe it for him. It would be interesting to hear from other T2's who have tight control over their diabetes using more traditional treatment and yet were precribed Afrezza as an alternative. I am also aware of the potential risks of using a GLP-1, but I can also say that convenience of a once weekly injection, which is relatively painless, outweighs using an inhaler 3 times a day. I am a staunch supporter of MNKD and I've been invested 7+ years, but I also know that not everyone is a candidate for Afrezza. decisions, decisions. Nadathing, From memory you asked your physician for Trulicity and feel it is right for you. You participated in the trial? You did get to decide.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TRULICITY safely and effectively. See full prescribing information for TRULICITY. TRULICITY (dulaglutide) injection, for subcutaneous use Initial U.S. Approval: 2014 WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. • Dulaglutide causes thyroid C-cell tumors in rats. It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined (5.1, 13.1). • TRULICITY is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors (4.1, 5.1).
pi.lilly.com/us/trulicity-uspi.pdf
|
|